

CUMULATIVE INDEX

Psychopharmacology Bulletin

A. Contents Index

Vol. 21, No. 1, 1985

- 1** **Annual NCDEU Meeting (1984)—
Abridged Proceedings—Consensus
Conferencing—**
- 2** Notes on the Consensus Development
Process — *David J. Kupfer and Mar-
garet C. McDonald*
- 7** An NIMH View of Consensus Confer-
encing — *Harold Alan Pincus*
**Carbamazepine in Psychiatric Disor-
ders —**
- 10** Carbamazepine in Bipolar Illness —
Robert M. Post and Thomas W. Uhde
- 18** Carbamazepine and Lithium: Differ-
ent Profiles in Affective Disorder? —
*Bernard Lerer, Norman Moore, Elaine
Meyendorff, Sung-Ran Cho, and Samuel
Gershon*
Medical Compliance —
- 23** Compliance in the Long-Term Treat-
ment of Schizophrenia — *John M.
Kane and Michael Borenstein*
- 28** Adherence to Methylphenidate Ther-
apy in a Pediatric Population: A Pre-
liminary Investigation — *Ronald T.
Brown, Kathi A. Borden, and Stephen R.
Clingerman*
- 37** Implications of Noncompliance on Re-
search in Affective Disorders — *Ellen
Frank, Robert F. Prien, David J. Kupfer,
and Lisa Alberts*
**Receptor Modulation as a Treatment
Strategy —**
- 43** Serotonin Agonists and Beta-Adrener-
gic Agonists as a Treatment for De-
pressive Disorder: A Direct Clinical
Application — *Stephen M. Stahl*

Blood Levels of Haloperidol and Clinical Response —

- 48** Haloperidol Plasma Levels and
Clinical Response: Basic Concepts and
Clinical Data — *John M. Davis, Stephen
E. Ericksen, Stephen Hurt, Sidney S.
Chang, Javaid I. Javaid, Haroutune
Dekirmenjian, and Regina Casper*
- 52** Haloperidol and Thioridazine Drug
Levels and Clinical Response in Schiz-
ophrenia: Comparison of Gas-Liquid
Chromatography and Radioreceptor
Drug Level Assays — *Robert C. Smith,
Richard Baumgartner, Alla Burd, G.K.
Ravichandran, and Mary Maudlin*
- 59** Does a Therapeutic Window for Plas-
ma Haloperidol Exist?: Preliminary
Chinese Data — *Steven G. Potkin,
Yucun Shen, Dongfeng Zhou, Herbert
Pardes, Liang Shu, Bruce Phelps, and
Russell Poland*
- 62** Plasma Haloperidol Levels and
Clinical Response: Confounding Vari-
ables — *Michael L. Mavroidis, David L.
Garver, Donald R. Kanter, and Jack Hir-
schowitz*
- 66** Absence of Relationship of Serum Hal-
operidol Concentration and Clinical
Response in Chronic Schizophrenia: A
Fixed-Dose Study — *Llewellyn B. Bige-
low, Darrell G. Kirch, Tammy Braum,
Esa R. Korpi, Richard L. Wagner, Steven
Zalcman, and Richard Jed Wyatt*
- 69** Plasma Levels of Haloperidol and
Clinical Response — *Theodore Van Put-
ten, Stephen R. Marder, Philip R.A. May,
Russell E. Poland, and Ronald P.
O'Brien*

Free Communications—Session A —

- 73 An Early Phase II Clinical Trial with Follow-up of Tomoxetine (LY139603) in the Treatment of Newly Admitted Depressed Patients — *G. Chouinard, L. Annable, J. Bradwejn, A. Labonte, B. Jones, P. Mercier, and M.-C. Belanger*
- 77 The Dexamethasone Suppression and TRH Stimulation Tests in the Initial Phase of Depression Treatment — *Javier I. Escobar, Angelos Halaris, Lewis Baxter, Glenn Schwarcz, Mark Thompson, Margo Lea Hurwicz, MaryAnn Hill, Melinda Young, Kathleen Daugherty, and April Clemens*
- 81 A Prospective Study of Lithium-Induced Nephropathy: Preliminary Results — *Jay D. Amsterdam, Diane Jorkasky, Larry Potter, and Malcolm Cox*
- 85 A Controlled Study of the Effects of Antidepressants on Sexual Function — *Wilma M. Harrison, Jonathan Stewart, Anke A. Ehrhardt, Judith Rabkin, Patrick McGrath, Michael Liebowitz, and Frederic M. Quitkin*
- 89 Effects of Naloxone on Cognitive Deficits Following Electroconvulsive Therapy — *Henry A. Nasrallah, Nils Varney, Jeffrey A. Coffman, John Bayless, and Suzanne Chapman*
- 91 Efficacy and Withdrawal of Two Potent Benzodiazepines: Bromazepam and Lorazepam — *R. Fontaine, L. Annable, P. Beaudry, P. Mercier, and G. Chouinard*
- 93 Psychomotor Performance Following the Long-Term Use of Benzodiazepines — *Irwin Lucki, Karl Rickels, and Andrew M. Geller*
- 97 Brotizolam in the Treatment of Insomnia — *Roberto A. Dominguez, Burton J. Goldstein, Alan F. Jacobson, and Richard M. Steinbock*
- 101 A Clinical Rating Scale for Symptoms of Psychosis in Alzheimer's Disease — *Barry Reisberg and Steven H. Ferris*
- Free Communications—Session B —**
- 105 FDA's Monitoring of Clinical Trials — *Walter Sloboda and Carolanne Currier*
- 107 Attrition and its Consequence in a Clinical Trial of Placebo, Imipramine, and Phenelzine — *Jeffrey S. Markowitz, Judith G. Rabkin, Patrick J. McGrath, Jonathan Stewart, and Frederic M. Quitkin*
- 110 Psychopharmacologic Treatment and Informed Consent: Empirical Research — *Barbara Stanley, Michael Stanley, Judith Stein, Lisa Guido, and Roxanna-Pentland Transit*
- 114 A Trial of Adjunctive Imipramine in Post-psychotic Depression — *Samuel G. Siris, Arthur Rifkin, Gerard T. Reedon, Seshagiri R. Dotti, Patricia Foster, and Elaine Casey*
- 117 Experience with a Drug-Free Month in Schizophrenic Outpatients — *Douglas W. Heinrichs and William T. Carpenter, Jr.*
- 120 A Comparison of the Clinical Effects of Bromperidol, a New Butyrophenone Derivative, and Haloperidol on Schizophrenia Using a Double-Blind Technique — *Hitoshi Itoh*
- 123 Methylphenidate Challenge Tests and Course of Schizophrenia — *Jeffrey A. Lieberman, John M. Kane, Dominick Gadaletta, Jorge Ramos-Lorenzi, Kenneth Bergmann, James Wegner, and Hana Novacenko*
- 130 Tardive Dyskinesia and Depressive Symptoms in Schizophrenics — *Mary Ann Richardson, Raymond Pass, Zachary Bregman, and Thomas J. Craig*
- 136 The Prevalence of Tardive Dyskinesia — *John M. Kane, Margaret Woerner, Jeffrey Lieberman, Paul Weinhold, William Florio, Morton Rubinstein, John Rotrosen, Janos Kurucz, Sukdeb Mukherjee, Kenneth Bergmann, and Nina R. Schooler*
- 140 Neuroleptic-Related Dyskinesias in Autistic Children: A Prospective Study — *Richard Perry, Magda Campbell, Wayne H. Green, Arthur M. Small, Maria L. Die Trill, Karen Meiselas, Robert R. Golden, and Stephen I. Deutsch*

- 144** Desipramine in the Treatment of Attention Deficit Disorder in Adolescents — *David R. Gastfriend, Joseph Biederman, and Michael S. Jellinek*
- 146** Amino Acid Precursors for the Treatment of Attention Deficit Disorder, Residual Type — *David R. Wood, Frederick W. Reimherr, and Paul H. Wender*
- 150** A Controlled Trial of Clomipramine in Childhood Obsessive-Compulsive Disorder — *Martine F. Flament, Judith L. Rapoport, Carol J. Berg, and Clinton Kilts*
- 153** **Cumulative Index—Psychopharmacology Bulletin—1984—**
Contents Index
Authors Index
- B-1** **Psychopharmacology—A Recurring Bibliography—**

Vol. 21, No. 2, 1985

- 167** **Introduction—Natalie Reatig**
Pharmacotherapy for ADD-H Adolescents Workshop —
- 169** Follow-up Studies on Outcome of Hyperactive Children — *Gabrielle Weiss*
- 178** Adolescent Outcome of Hyperactive Children Treated with Stimulants in Childhood: A Review — *Lily Hechtman*
- 192** Pharmacotherapy in ADD Adolescents with Special Attention to Multimodality Treatments — *Ronald T. Brown, Kathi A. Borden, and Stephen R. Clingerman*
- 212** Prevalence of Medication Treatment for Hyperactive Adolescents — *Daniel J. Safer and John M. Krager*
- 216** A Review of Studies of Drug Treatment Efficacy with Attention Deficit Disorder with Hyperactivity in Adolescents — *Christopher K. Varley*
- 222** Pharmacological Treatment of Attention Deficit Disorder, Residual Type (ADDRT, "Minimal Brain Dysfunction," "Hyperactivity" in Adults) — *Paul H. Wender, David R. Wood, and Fred W. Reimherr*
- 232** New Drug Trials in Attention Deficit Disorder — *Judith L. Rapoport, Alan Zametkin, Maureen Donnelly, and Deborah Ismond*
- 237** Diagnosing ADD-H in Adolescents — *Rachel Gittelman and Salvatore Mannuzza*
- 243** Issues in the Study of Adolescent ADD-Hyperactivity — *C. Keith Conners*
- A Summary of the Workshop Proceedings**
- 251** Pharmacotherapy of ADD in Adolescents: What Do We Know, Where Should We Go, How Should We Do It? — *Dennis P. Cantwell*
- Pharmacotherapy and Mental Retardation Workshop —**
- 258** Emotional Problems in the Mentally Retarded: The Need for Assessment and Treatment — *Johnny L. Matson*
- 262** Issues in Pharmacology with the Mentally Retarded — *Susan Mouchka*
- 268** Psychoactive Drug Use in Public and Community Residential Facilities for Mentally Retarded Persons — *James Intagliata and Chris Rinck*
- 279** A National Study of Prescribed Drugs in Institutions and Community Residential Facilities for Mentally Retarded People — *Bradley K. Hill, Elizabeth A. Balow, and Robert H. Bruininks*
- 285** Establishing Socially Validated Drug Research in Community Settings — *Martin Agran and James E. Martin*
- 291** Prevalence and Efficacy of Stimulant Drug Use with Mentally Retarded Children and Youth — *Kenneth D. Gadow*

- 304** Psychopharmacology in the Mentally Retarded and a Few Related Issues — *C. Thomas Gualtieri and J.M. Keppel*
- 310** Behavioral Interactions Induced by Chronic Neuroleptic Therapy in Persons with Mental Retardation — *Stephen R. Schroeder and C. Thomas Gualtieri*
- 316** Diagnosis and Pharmacotherapy of Schizophrenia in the Retarded — *Frank J. Menolascino, Stephen L. Ruedrich, Charles J. Golden, Ph.D., and James E. Wilson, Pharm.D.*
- Workshop Summary —**
- 323** Issues and Future Research Directions of Pharmacotherapy in Mental Retardation — *Stephen R. Schroeder*
- Brief Report —**
- 327** An Applied Tardive Dyskinesia Monitoring System (ATDMS) — *John E. Kalachnik*
- 329** Pharmacotherapy and Mental Retardation/Developmental Disability: A Bibliography — *Natalie Reatig*
- Adverse Drug Reaction —**
- 334** "Time-less" Risks (A Hazard of Risk Assessment: The Example of Seizure and Antidepressants) — *Paul Leber*
- Articles —**
- 339** ACTeRS Useful in Screening Learning Disabilities from Attention Deficit Disorder (ADD-H) Children — *Rina K. Ullmann*
- 345** Carbamazepine in Tardive Dyskinesia — *András Perényi and Dániel Sztanisláv*
- 347** Biochemistry of Alzheimer's Disease — *Ira R. Berry and Lionel Borkan*
- B-1 Psychopharmacology—
A Recurring Bibliography—**
- 357 In the Pipeline—Barry Blackwell**
- 23rd Meeting of the ACNP—1984—
Abridged Proceedings —**
- New Approaches to the Genetics of
Psychiatric Disorders —**
- 361** Additional Cerebrospinal Fluid Proteins Found in Schizophrenia and Creutzfeldt-Jakob Disease — *Michael G. Harrington and Carl R. Merril*
- 365** Cerebral Ventricular Enlargement as a Possible Genetic Marker for Schizophrenia — *Lynn E. DeLisi, Lynn R. Goldin, Joel R. Hamovit, M. Elizabeth Maxwell, David Kurtz, John I. Nurnberger, and Elliot S. Gershon*
- Bright Light, Melatonin, and Biological Rhythms: Implications for the Affective Disorders —**
- 368** Treating Phase Typed Chronobiologic Sleep and Mood Disorders Using Appropriately Timed Bright Artificial Light — *Alfred J. Lewy, Robert L. Sack, and Clifford M. Singer*
- New Strategies in the Therapy of Affective Disorders —**
- 373** The Serotonin/Norepinephrine-Linked Beta-Adrenoceptor System and the Mode of Action of Antidepressant — *Elaine Sanders-Bush, P. Jeffrey Conn, and Fridolin Sulser*
- 379** Serotonergic Modulation of Cortical Rat Noradrenergic System in the Mechanism of Action of Antidepressant Drugs — *N. Brunello, I. Mucchetti, A. Volterra, V. Cuomo, and G. Racagni*
- 385** The GABA Hypothesis of Depression and Antidepressant Drug Action — *G. Bartholini, K.G. Lloyd, B. Scatton, B. Zivkovic, and P.L. Morselli*

Do We Need CSF Studies in Clinical Pharmacology? —

- 389** CSF, Plasma, and Urine: What Do Concomitant Measurements of Norepinephrine and Its Metabolites Mean? — *Markku Linnoila, Elizabeth A. Lane, Sally Guthrie, Ioanis Parashos, Matthew Rudorfer, and William Z. Potter*
- 396** Can CSF Measures Distinguish Among Schizophrenia, Depression, Movement Disorders, and Dementia? — *Stephen M. Stahl*
- 400** Clinical Implications of Neurochemical Mechanisms of Appetite Regulation—Neuropeptidergic Regulation of Feeding — *John E. Morley, Blake A. Gosnell, Dean D. Krahn, James E. Mitchell, and Allen S. Levine*
- 406** Peptide-Catecholamine Interaction: Feeding and Satiety — *Robert D. Myers*
- 412** Brain Neurotransmitters and Appetite Regulation — *Sarah F. Leibowitz*
- 419** Disturbances of Norepinephrine Metabolism and α -2 Adrenergic Receptor Activity in Anorexia Nervosa: Relationship to Nutritional State — *Walter H. Kaye, Harry E. Gwirtsman, C. Raymond Lake, Larry J. Siever, David C. Jimerson, Michael H. Ebert, and Dennis L. Murphy*
- Pharmacologic Model of Anxiety in Man —**
- 424** Isoproterenol-Induced Anxiety States — *Robert Pohl, John Rainey, Aurelio Ortiz, Richard Balon, Heminder Singh, and Richard Berchou*
- 428** The Lactate Infusion Model — *Jack M. Gorman, Donald Dillon, Abby J. Fyer, Michael R. Liebowitz, and Donald F. Klein*
- 434** Panic Anxiety and Lactate Metabolism — *John M. Rainey, Jr., Charles E. Frohman, Ken Warner, Stewart Bates, Robert B. Pohl, and Vikram Yeragani*
- Biological and Behavioral Reactions to Stress —**
- 438** Regulation of Adrenocorticotropin Release From the Anterior Pituitary — *Terry Reisine*
- 443** Melancholia in Rodents: Neurobiology and Pharmacology — *Fritz A. Henn, Joel Johnson, Emmeline Edwards, and David Anderson*
- 447** Neurochemical Basis of Stress-Induced Depression — *Jay M. Weiss and Prudence Goodman Simson*
- 458** Serotonin-Behavior Interactions in Vervet Monkeys — *Michael T. McGuire and Michael J. Raleigh*
- Enkephalin-Endorphins: Emotional Stress, Depression, and the Immune System —**
- 464** Selectivity of Opioid Agonists and Antagonists for the Various Opioid Receptor Types — *A.E. Takemori and P.S. Portoghese*
- 466** Opioid Peptides in the Adrenal Pituitary Axis — *Christopher J. Evans, Elizabeth Erdelyi, and Jack D. Barchas*
- 472** The Alpha MSH-Specific and Arcuate Pro-Opiomelanocortin Neuronal Systems of the Hypothalamus: Observations on Their Connectivity and Response to Colchicine Treatment — *Karl M. Knigge, Diane T. Piekut, and Shirley A. Joseph*
- 476** Depression, Hypothalamic-Pituitary-Adrenocortical Activity, and Lymphocyte Function — *Ziad Kronfol and J. Daniel House*
- 479** Involvement of Opioid Peptides in the Analgesic, Immunosuppressive, and Tumor-Enhancing Effects of Stress — *James W. Lewis, Yehuda Shavit, Gregory W. Terman, Linda R. Nelson, Frederick C. Martin, Robert Peter Gale, and John C. Liebeskind*
- 485** Endorphins, Immune Function, and Cancer — *John E. Morley, Neil Kay, John Allen, Timothy Moon, and Charles J. Billington*
- 489** The Ying-Yang Hypothesis of Opioid Peptide Immunomodulation — *Nicholas P. Plotnikoff*

Psychobiological Markers for Schizophrenia: State of the Art and Future Perspectives —

- 490** Introduction and Summary — *Joseph Zubin*
- 497** Are There State-Dependent Markers in Schizophrenia? — *Daniel P. van Kammen, Jules P. Rosen, Jeffrey Peters, Robert Fields, and Welmoet B. van Kammen*
- 503** Vulnerability to Schizophrenia: Childhood Indicators Predict Adult Outcome — *Ernest Hartmann, Walter Mitchell, Patricia Brune, and Daniel Greenwald*
- 509** Distractibility as a Marker of Vulnerability to Schizophrenia — *Bonnie Spring*
- 513** Neurophysiological Aspects of Information Processing in Schizophrenia — *Stuart R. Steinhauser*
- 518** Sensory and Perceptual Behavioral Markers of Schizophrenia — *Mitchell L. Kietzman*

Neuropeptides Modulating Dopaminergic Function: New Horizons for the Dopamine Hypothesis of Schizophrenia —

- 523** Cholecystokinin Potentiates Dopamine-Mediated Behaviors in the Nucleus Accumbens, a Site of CCK-DA Co-Existence — *Jacqueline N. Crawley*

Toxic Effects of Psychomotor Stimulants —

- 528** Persistent Effects of Amphetamine, *p*-Chloroamphetamine, and Related Compounds on Central Dopamine and Serotonin Neurons in Rodents — *Ray W. Fuller*

Alternate Treatment Strategies in Schizophrenia: Focus on the Deficit State —

- 533** High-Dose Versus Low-Dose Strategies in the Treatment of Schizophrenia — *John M. Kane, Arthur Rifkin, Margaret Woerner, Gerald Reardon, Dolores Kreisman, Richard Blumenthal, and Michael Borenstein*

Panic Disorder and Major Depression: Epidemiology, Family Studies, Biologic, and Treatment Response Similarities —

- 538** The Epidemiology of Anxiety Disorders: A Highlight of Recent Evidence — *Myrna M. Weissman, Philip J. Leaf, Charles E. Holzer III, and Kathleen R. Merikangas*
- 543** Major Depression and Panic Disorder: A Family Study Perspective — *James F. Leckman, Myrna M. Weissman, Kathleen R. Merikangas, David L. Pauls, Brigitte A. Prusoff, and Kenneth K. Kidd*
- 546** Neuroendocrine Abnormalities in Panic Disorder — *Peter P. Roy-Byrne, Thomas W. Uhde, Philip W. Gold, David R. Rubinow, and Robert M. Post*
- 551** Panic Disorder and Major Depression: Biological Relationships — *Peter P. Roy-Byrne and Thomas W. Uhde*
- 555** Lactate Infusion in Patients With Depression and Anxiety — *Patrick J. McGrath, Jonathan W. Stewart, Wilma Harrison, Frederic M. Quitkin and Judith Rabkin*
- 558** Effect of Panic Attacks on the Treatment of Atypical Depressives — *Michael R. Liebowitz, Frederic M. Quitkin, Jonathan W. Stewart, Patrick J. McGrath, Wilma Harrison, Judith Rabkin, Elaine Tricamo, Jeffrey S. Markowitz, and Donald F. Klein*
- 562** Panic Attacks in Outpatients With Depression: Response to Antidepressant Treatment — *Donald S. Robinson, Allen Kayser, John Corcella, Desmond Laux, Kevin Yingling, and Diantha Howard*
- Hormones and Depression—An Update —**

- 568** Hormones and Depression—Conceptual Transitions — *Uriel Halbriech*

Peripheral Models for the Study of Neurotransmitter Receptors in Man —

- 573** Yohimbine and Clonidine Recognize Different States of Adrenergic Receptors on Human Platelets: Reconsideration of Studies on Platelet Alpha-2 Receptors in Depressive Illness — *John E. Piletz and Angelos Halaris*

- 579** Nocturnal Serum Melatonin in Major Depressive Disorder Before and After Desmethylimipramine Treatment — *Richard P. Brown, Stanley Caroff, James J. Kocsis, Jay Amsterdam, Andrew Winokur, Peter Stokes, and Alan Frazer*

Patterns of Cognitive Effects of Somatic Therapies —

- 582** Effect of Neuroleptic Treatments on Attention, Information Processing, and Thought Disorder — *Herbert E. Spohn, Lolafaye Coyne, Fred Mittleman, Jan Larson, Mary Johnston, Judy Spray, and Kenneth Hayes*

Brain Imaging in Psychiatry: New Developments —

- 588** Magnetic Resonance Imaging Studies of Schizophrenia — *Robert C. Smith, Richard Baumgartner, Marcos Calderon, Awatif Affas, G.K. Ravichandran, and I. Donald Peters*

- 595** Dopamine Receptor Binding of C-11-3-N-Methylspiperone in the Caudate in Schizophrenia and Bipolar Disorder: A Preliminary Report — *Dean F. Wong, Henry N. Wagner, Jr., Godfrey Pearlson, Robert F. Dannals, Jonathan M. Links, Hayden Ravert, Alan Wilson, Sudhir Suneja, Eythor Bjorrvinssen, Michael J. Kuhar, and Larry Tune*

Studies of Peripheral Monoamine Receptors in Affective Illness —

- 599** Platelet Alpha-Adrenergic Receptor Function in Affective Disorders and Schizophrenia — *Marian S. Kafka, Larry J. Siever, John I. Nurnberger, Thomas W. Uhde, Steven Targum, Dermot M.J. Cooper, Daniel P. van Kammen, and Nancy S. Tokola*

- 603** Studies of Beta-Adrenergic Receptors in Leukocytes of Patients With Affective Illness and Effects of Antidepressant Drugs — *Ghanshyam N. Pandey, Philip Janicak, and John M. Davis*

Social Phobias: Diagnosis, Pathophysiology, and Treatment —

- 610** Psychopharmacological Treatment of Social Phobia — *Michael R. Liebowitz, Jack Gorman, Abby Fyer, Raphael Campeas, Andrew Levin, Sharon Davies, and Donald F. Klein*

- 615** Behavioral Treatment of Social Phobia — *Isaac Marks*

Improvement With Antidepressants: Timing and Relationship to Biochemical Events —

- 619** Delayed Biochemical Changes Following Antidepressant Treatment — *Michael F. Sugrue*

Pharmacogenetics: A Preclinical and Clinical Perspective —

- 623** Molecular Basis of Drug-Resistance Mutations in *C. Elegans* — *James B. Rand and Richard L. Russell*

- 631** Biophysical Alterations in Cell Membranes Associated With Psychotherapeutic Drug Exposure, Psychopathology, and Aging — *George S. Zubenko and Bruce M. Cohen*

- 641** Relevance of Genetic Variability to Clinical Psychopharmacology — *Bruce M. Cohen and George S. Zubenko*

Noradrenergic Mechanisms and the Drug Withdrawal Syndrome —

- 651** Adrenergic Agonist Therapy in Alcohol Withdrawal States in Man — *Paul Cushman, Jr., William Lerner, and Michael Cramer*

Targeting the Central Nervous System: New Drug Delivery Technologies for Psychotropic Agents —

- 657** Chemical Approaches to Drug Delivery to the Central Nervous System — *Colin R. Gardner*
- 663** Peripheral Models for the Study of Neurotransmitter Receptors in Man — *Stephen M. Stahl*
- 672** Implantable Narcotic Antagonists: A Possible New Treatment for Narcotic Addiction — *C. Nora Chiang, Akira Kishimoto, Gene Barnett, and Leo E. Hollister*

Pharmacologic Challenge Strategies in Alzheimer's Disease: Basic and Clinical Issues —

- 676** Cognitive and Behavioral Sensitivity to Scopolamine in Alzheimer Patients and Controls — *Trey Sunderland, Pierre Tariot, Edward A. Mueller, Dennis L. Murphy, Herbert Weingartner, and Robert M. Cohen*
- 680** Low- and High-Dose Naloxone in Dementia of the Alzheimer Type — *Pierre N. Tariot, Trey Sunderland, Herbert Weingartner, Dennis L. Murphy, Martin R. Cohen, and Robert M. Cohen*

Poster Session — Editor's Choice

- 683** The Window of Vulnerability in the Ontogeny of the Dopamine Receptor — *Jeanette C. Miller and Arnold J. Friedhoff*
- 686** Depression in Adults With a History of Prenatal DES Exposure — *Heino F.L. Meyer-Bahlburg, Anke A. Ehrhardt, Jean Endicott, Norma P. Veridiano, E. Douglas Whitehead, and Felix H. Vann*
- 690** Cortisol and Prolactin Responses to Dexamethasone in Major Depression, Chronic Pain, and Chronic Pain With Major Depression — *Joseph H. Atkinson, Jr., Edwin F. Kremer, S. Craig Risch, and David S. Janowsky*

- 694** Evidence for a Daily Rhythm of Plasma HVA in Normal Controls But Not in Schizophrenic Patients — *Allen R. Doran, David Pickar, Rodrigo Labarca, Patrice Douillet, Owen M. Wolkowitz, John W. Thomas, Alex. Roy, and Steven M. Paul*

- 698** Imipramine for Treatment of Chronic Depression — *James H. Kocsis, Allen Frances, J. John Mann, John Sweeney, Carlyle Voss, Barbara Mason, and Richard P. Brown*

- 701** A New Postsynaptic Serotonin Receptor Agonist Suitable for Studies in Humans — *Edward A. Mueller, Dennis L. Murphy, Trey Sunderland, and Julia Jones*

- 705** Addition of Estrogen to Imipramine in Female-Resistant Depressives — *Joseph Zohar, Baruch Shapira, Gerald Oppenheim, Frank J. Ayd, and Robert H. Belmaker*

- 707** Lidocaine Kindling is Accompanied by an Increase in Apomorphine Stereotype and Mesolimbic Dopamine D Receptor Density — *John G. Csernansky, Cynthia A. Csernansky, Seth A. Glick, and Leo E. Hollister*

Vol. 21, No. 4, 1985

RATING SCALES AND ASSESSMENT INSTRUMENTS FOR USE IN PEDIATRIC PSYCHOPHARMACOLOGY RESEARCH

- 713** From the Editor's Desk —

- 714** Introduction to This Issue — *Judith L. Rapoport and C. Keith Conners*

Demographic Data and Family History —

- 719 *Documentation of Demographic Data and Family History of Psychiatric Illness — Magda Campbell and Michael Palij**

- 722 Demographic Template — Magda Campbell**

- 728 ROS (Research Obstetrical Scale) — Arnold J. Sameroff, R. Seifer, and M. Zax**

- 731 Prior Medication Record — NIMH**

Psychiatric Interviews —

- 737 *Psychiatric Interviews Suitable for Use in Research With Children and Adolescents — Helen Orvaschel**

- 747 CGAS (A Children's Global Assessment Scale) — David Shaffer, Madelyn S. Gould, James Brasic, Paul Ambrosini, Prudence Fisher, Hector Bird, and Satwant Aluwahlia**

- 749 Rutter-Graham Psychiatric Interview for Children — Michael Rutter and Philip Graham**

- 753 Children's Psychiatric Rating Scale (Scoring) — Barbara Fish**

- 765 Children's Psychiatric Rating Scale — NIMH**

Neurological Examinations —

- 773 Revised Physical and Neurological Examination for Subtle Signs — Martha Bridge Denckla**

- 780 Scoring for Revised Physical and Neurological Examination for Subtle Signs — Martha Bridge Denckla**

- 793 PANESS (Physical and Neurological Examination for Soft Signs) — NIMH**

Diagnosis —

- 803 *DSM-III-R Pediatric Psychopharmacology — Judith L. Rapoport**

Rating Scales and Checklists for Psychopharmacologic Trials —

- 809 *Rating Scales and Checklists for Child Psychopharmacology — C. Keith Conners and Russell A. Barkley**

- 816 Parent Symptom Questionnaire — C. Keith Conners**

- 823 Teacher Questionnaire — C. Keith Conners**

- 828 Teacher Questionnaire (Follow-up School Report) — C. Keith Conners**

- 832 IGRS (Inpatient Global Rating Scale) — C. Keith Conners**

- 835 Child Behavior Rating Form — Craig Edelbrock**

- 839 CGI (Clinical Global Impression) Scale — NIMH**

- 845 The Aberrant Behavior Checklist — Michael G. Aman, Nirbhay N. Singh, Alis-tair W. Stewart, and Carolyn J. Field**

- 851 GSS (General Scoring Sheet)—Basic — NIMH**

Measures of Social Skills —

- 855 *Development of a Rating Scale to Measure Social Skills in Children: The Matson Evaluation of Social Skills With Youngsters (MESSY) — Johnny L. Matson, Anthony F. Rotatori, and William J. Helsel**

- 861 Matson Evaluation of Social Skills With Youngsters (MESSY): (Teacher Rating Form) — Johnny L. Matson and Karen Esveltd-Dawson**

- 865 Matson Evaluation of Social Skills With Youngsters (MESSY): (Self-Rating Form) — Johnny L. Matson and Karen Esveltd-Dawson**

- 869 Social Interaction Observation Code — Howard Abikoff, Diane Martin, and Rachel Gittelman**

Performance Measures —

***PLEASE NOTE:** All references in this paper are presented in a single reference section to be found on pages 1111-1124.

877 *Assessing Drug Effects on Academic Performance — *Kenneth D. Gadow and H. Lee Swanson*

887 *Measures of Cognitive Functioning Appropriate for Use in Pediatric Psychopharmacology Research Studies — *James M. Swanson*

891 *The Computerized Continuous Performance Test — *C. Keith Conners*

893 *Measuring Activity Level in Children — *C. Keith Conners*

898 Hillside Behavior Rating Scale (Behavior During Testing) — *Rachel Gittelman and Donald Klein*

901 Classroom Observation Code: A Modification of the Stony Brook Code — *Howard Abikoff and Rachel Gittelman*

Ratings for Attention Deficit Disorders —

913 *Some Thoughts on the Diagnosis of ADD-H in Adolescents — *Rafael Klorman*

915 Introduction to the Use of ACTeRS — *Rina K. Ullmann, Esther K. Sleator, and Robert L. Sprague*

917 ACTeRS (ADD-H Comprehensive Teacher's Rating Scale) —

921 ADD-H Adolescent Self-Report Scale — *C. Keith Conners and Karen C. Wells*

923 Parent Questionnaire of Teenage Behavior (Modified Conners) — *Rachel Gittelman*

925 Self-Evaluation (Teenager's) Self-Report — *Rachel Gittelman*

927 AQCC (Adult Questionnaire-Childhood Characteristics) Scale — *Paul H. Wender*

929 Bibliography on Rating and Assessment Instruments for Attention Deficit Disorder (ADD) — *Natalie Reatig*

Ratings for Anxiety Disorders —

***PLEASE NOTE:** All references in this paper are presented in a single reference section to be found on pages 1111-1124.

933 Ratings for Anxiety Disorders — *Rachel Gittelman*

934 Children's Manifest Anxiety Scale: Parent Ratings — *Rachel Gittelman*

936 Children's Manifest Anxiety Scale: Child Ratings — *Rachel Gittelman*

939 Parent's Questionnaire (Modified Conners): Anxiety and Mood Items Added — *Rachel Gittelman*

945 Teacher Rating Scale ((Modified Conners): Anxiety and Mood Items Added — *Rachel Gittelman*

Ratings for Childhood Depression —

951 *Scales of Potential Use in the Psychopharmacologic Treatment of Depressed Children and Adolescents — *Theodore A. Petti*

957 DMS-III Symptom Checklist for Major Depressive Disorders — *Javad Kashani, Donald McKnew, and Leon Cytryn*

959 BID (The Bellevue Index of Depression) — *Theodore A. Petti*

969 PNID (Peer Nomination Index of Depression) — *M. M. Lefkowitz and E. Tesing*

972 SADLI (School Age Depression Listed Inventory) — *Theodore A. Petti*

976 Interview for the SADLI — *Theodore A. Petti*

979 Children's Depression Rating Scale-Revised — *Elva O. Poznanski*

991 ISC (The Interview Schedule for Children) — *Maria Kovacs*

995 CDI (The Children's Depression Inventory) — *Maria Kovacs*

Ratings for Eating Disorders —

1001 *Rating Scales in the Eating Disorders — *Katherine A. Halmi*

- 1004** Anorexic Behavior Scale — *Peter D. Slade*
- 1005** Anorectic Attitude Questionnaire — *Solomon C. Goldberg, Katherine A. Halmi, and Elke D. Eckert*
- 1008** Eating Attitudes Test — *David M. Garner and Paul E. Garfinkel*
- 1009** Eating Disorder Inventory — *David M. Garner, M. P. Olmsted, and J. Polivy*
- 1011** Binge Scale Questionnaire — *Raymond C. Hawkins and Pamela F. Clement*
- 1013** Binge-Eating Questionnaire — *Katherine A. Halmi, James R. Falk, and Estelle Schwartz*
- 1017** Bulimia Interview Form — *Timothy Walsh and Madeline Gladis*
- 1025** Eating Disorders Questionnaire — *James E. Mitchell*
- Ratings for Autism —**
- 1047** *Behavioral and Cognitive Measures Used in Psychopharmacological Studies of Infantile Autism — *Magda Campbell and Michael Paliz*
- 1053** CARS (Childhood Autism Rating Scale) — *E. Schopler, R. J. Reichler, and B. R. Renner*
- Ratings for Obsessive-Compulsive Disorders —**
- 1057** The Leyton Obsessional Inventory-Child Version — *Carol J. Berg, Judith L. Rapoport, and Martine Flament*
- Rating for Adverse Effects —**
- 1063** *Measurement of Side Effects Including Tardive Dyskinesia — *Magda Campbell*
- 1067** DOTES (Dosage Record and Treatment Emergent Symptom Scale) — *NIMH*
- 1069** TESS (Treatment Emergent Symptoms Scale—Write-In) — *NIMH*
- 1073** STESS (Subjective Treatment Emergent Symptoms Scale) — *NIMH*
- 1077** AIMS (Abnormal Involuntary Movement Scale) — *NIMH*
- 1081** Protocol for Rating Drug-Related AIMS, Stereotypies, and CPRS Assessments — *Magda Campbell*
- 1082** Timed Stereotypies Rating Scale — *Magda Campbell*
- 1085** Laboratory Tests for Drug Studies — *Judith L. Rapoport*
- Measures of Medication Compliance —**
- 1089** *Measurement of Compliance — *Esther K. Sleator*
- Grant Support and Ethical Issues —**
- 1097** The Grant Support Program of the Pharmacologic and Somatic Treatment Research Branch — *Natalie Reatig*
- 1100** DHHS Internal Policies for Reviewing Protections to Human Subjects in Research — *Natalie Reatig*
- 1105** Ethical Issues in Research With Children: A Bibliography — *Natalie Reatig*
- 1111** References for All Starred * Papers —

***PLEASE NOTE:** All references in this paper are presented in a single reference section to be found on pages 1111-1125.